Connect with us

Technology

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

Published

on

IRVING, Texas, May 8, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP), administered through the Wadsworth Center, seeking authorization to perform Caris Assure®, its blood‑based molecular profiling test, on specimens originating from New York State.

Caris Assure is a blood‑based molecular profiling test designed to support comprehensive biomarker analysis using a minimally invasive blood sample. Caris Assure uses circulating nucleic acids sequencing (cNAS) to analyze the whole exome (DNA) and whole transcriptome (RNA) of 22,000 genes. This comprehensive test identifies tumor alterations, clonal hematopoiesis (CH) and inherited variants, pharmacogenomic alterations, microsatellite instability (MSI) and tumor mutational burden (TMB).

The submission initiates the formal review process required by New York State for clinical laboratories seeking to perform testing on specimens collected from New York patients. Through the Wadsworth Center, CLEP conducts comprehensive reviews of laboratory permits and laboratory-developed tests to evaluate analytical validation, quality systems, personnel qualifications and compliance with applicable state regulations.

“Caris is committed to meeting the highest standards for laboratory quality, validation and regulatory compliance,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “This submission of Caris Assure for review through the New York State Department of Health’s Wadsworth Center reflects our disciplined approach to expanding access to our technologies in a manner that demonstrates the rigor, responsibility and focus on the patient that define Caris Life Sciences and guide our work in the markets we serve.”

At this time, no determination has been made by NYSDOH, and Caris Assure is not authorized for use on blood-based specimens originating from New York State unless and until CLEP authorization is granted.

Caris operates a CAP-accredited, CLIA‑certified clinical laboratory and performs testing in jurisdictions where it is authorized to do so, in accordance with all applicable federal, state, and local regulations. Any future availability of Caris Assure in New York State will be contingent upon completion of the CLEP review process administered by the Wadsworth Center and receipt of the appropriate authorization.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-submits-application-to-new-york-state-department-of-health-for-caris-assure-bloodbased-testing-authorization-302767104.html

SOURCE Caris Life Sciences

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BitradeX BXC First Two Subscription Rounds Sell Out, Total Subscriptions Exceed 14M USDT

Published

on

By

LONDON, May 9, 2026 /PRNewswire/ — BitradeX Capital’s ecosystem equity token, BXC, has completed its first and second subscription rounds, selling a total of 50 million BXC with subscriptions exceeding 14 million USDT. The first round sold out in 90 seconds, while the second closed within 48 hours.

While the fundraising size is not unusually large by crypto standards, the structure of the sale has attracted market attention. The first two rounds were not open to the public, but limited to high-tier BitradeX users. The first round was available only to V5 users and above, while the second round expanded access to V3 users and above.

According to BitradeX’s tier system, V3+ users typically have higher recurring investment activity through AiBot, longer platform usage history, and stronger ecosystem participation. This means the early BXC allocation was absorbed mainly by the platform’s internal high-value user base, rather than short-term speculative participants.

This approach differs from many token fundraising campaigns that prioritize broad public participation and market hype. BitradeX instead adopted a more selective, staged model, gradually lowering the participation threshold while keeping the sale within its active ecosystem community.

BXC is positioned as more than a standard platform token. Its value framework is linked to BitradeX Capital’s broader ecosystem, including its exchange business, AiBot quantitative strategies, BTX Card payments, and Labs incubation platform. Public information indicates that BXC holders may receive staking rewards, benefit from ecosystem buybacks and burns, and gain priority access to Launchpad projects and governance participation.

The third subscription round is launched on April 30 at $0.35 USDT per BXC, with a total supply of 100 million BXC. It is now open to users participating in AiBot recurring investment. The fourth round price is expected to rise to $0.45 USDT.

The long-term value of BXC will ultimately depend on the growth of BitradeX’s underlying businesses, including exchange profitability, AiBot user expansion, and BTX Card adoption. However, the rapid sellout of the first two rounds suggests that BitradeX’s core user base has already shown strong confidence in the ecosystem’s future.

View original content:https://www.prnewswire.com/news-releases/bitradex-bxc-first-two-subscription-rounds-sell-out-total-subscriptions-exceed-14m-usdt-302767467.html

SOURCE BitradeX Capital

Continue Reading

Technology

South and East Asia identified as hotspots of global warming related impacts on male fertility

Published

on

By

BEIJING, May 9, 2026 /PRNewswire/ — A major new study has shown that South and East Asia dominate patterns of global warming related decline in male fertility with the strongest and most consistent evidence coming from India, Pakistan and the southern parts of China.

The effects of increased environmental temperatures on male reproductive health include declining sperm concentration and motility and increased sperm DNA fragmentation, or genetic damage that can hinder fertilisation and embryo development.

Male related factors account for around 50 per cent of infertility cases around the world and the impact of rising ambient heat on semen parameters raises serious implications across wide areas of Asia where total fertility rates are in serious decline.

Outcomes of the study undertaken by the Taiwan IVF Group and Ton Yen General Hospital, Taiwan (China) in collaboration with Stanford University (USA) are being presented at the 2026 Congress of the Asia Pacific Initiative on Reproduction (ASPIRE) in Beijing.

Research principal and Adjunct Clinical Assistant Professor at Stanford University, Dr Jack Yu Jen Huang, MD, PhD, FACOG said: “Given the temperature sensitivity of spermatogenesis, even modest increases in ambient temperature could have cumulative, population-level effects over time.

“As global warming accelerates, male reproductive health may represent an emerging climate sensitive public health concern.”

The testes function optimally at temperatures lower than the internal body heat level, and previous studies have shown elevated scrotal or ambient temperatures can impair sperm production.

The latest research explored global patterns to reveal comparative data across regions. It is based on a systematic review of international studies on temperature exposure and semen parameter trends between 2000 and 2024. Artificial intelligence algorithms and machine learning tools were applied to extract key variables including geographic regions and semen outcomes.

Dr Huang said studies examining occupational heat exposure alone were excluded from the analysis as they reflected localised, job-specific conditions rather than broader climatic trends.

“Our findings therefore represent population level climate associated temperature effects including consistent seasonal variations showing poor semen quality parameters in warmer periods.”

The global patterns on temperature associated lower sperm concentration and motility show South and East Asia as major hot spots of concern followed by the Middle East, Europe and North America.

“South and East Asia are likely more affected due to a combination of factors including higher baseline ambient temperatures and rapid urbanisation that contribute to greater cumulative heat stress on spermatogenesis,” Dr Huang explained.

“With ongoing global warming, chronic heat exposure may increasingly impact male reproductive health.”

Dr Huang said potential approaches to address the issue include:

increasing public awareness of heat exposure and reproductive health;encouraging protective behaviours;expanding research integrating climate and reproductive health data; andexploring clinical and lifestyle interventions to mitigate heat-related effects.

The research team was assisted by research intern Jeffrey Zi Kang Huang from Taipei American School, particularly in the application of artificial intelligence in biomedical research including AI-assisted data analysis and pattern recognition across global datasets.

“Further longitudinal and mechanistic studies will be important to better define causality and guide interventions,” he added.

The ASPIRE Congress is being held at the China National Convention Centre in Beijing. More than 3,000 scientists, clinicians, nurses and counsellors in assisted reproduction from around the world are attending the Congress.

For further information, go to https://www.aspire2026.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/south-and-east-asia-identified-as-hotspots-of-global-warming-related-impacts-on-male-fertility-302767469.html

SOURCE ASPIRE

Continue Reading

Technology

eclicktech Attends Amazon Ads unBoxed 2026, Highlighting Four Key Trends Shaping AI-Driven Global Marketing

Published

on

By

SHENZHEN, China, May 9, 2026 /PRNewswire/ — Amazon Ads recently hosted its annual flagship event, Amazon Ads unBoxed 2026, in Shenzhen, bringing together advertisers, agencies, and technology partners to explore the next phase of AI-powered marketing innovation. This year’s event focused on how AI is reshaping the advertising ecosystem through advancements in audience targeting, creative production, campaign management, and measurement capabilities.

Yeahmobi, the global marketing brand under eclicktech and an Amazon DSP validated partner, attended the event alongside industry leaders and ecosystem partners to discuss emerging opportunities for international brand growth in an increasingly AI-driven media environment.

During the conference, Amazon Ads introduced a series of product and solution updates across four major areas:

Advanced audience targeting powered by Amazon’s first-party data infrastructure to help brands reach high-intent consumers more effectively;AI-assisted creative production designed to improve content efficiency and support personalized advertising at scale;Intelligent campaign management tools aimed at simplifying cross-channel advertising workflows;Enhanced measurement and attribution capabilities to provide advertisers with clearer visibility into campaign performance and return on investment.

According to Yeahmobi, Amazon DSP is evolving beyond a standalone programmatic buying platform into a broader marketing infrastructure supporting the full customer journey, from brand awareness to conversion.

Since becoming an Amazon Ads partner, Yeahmobi has developed integrated advertising solutions spanning awareness, audience engagement, and conversion optimization. The company stated that it has supported brands across sectors including cross-border e-commerce, consumer electronics, AI applications, and financial services in scaling their global advertising efforts through Amazon DSP.

At the event, Yeahmobi also showcased its proprietary advertising management platform, Yeahgrowth, which integrates campaign management, data analytics, and performance optimization capabilities to support centralized multi-platform operations and improved campaign visibility.

“AI is fundamentally reshaping how brands approach global growth,” said William Liu, General Manager of Yeahmobi. “We see Amazon Ads as a strategically important part of the global marketing ecosystem. Our focus is not only on media execution, but also on building scalable growth infrastructure through deeper API integration, AI-driven optimization, and data collaboration.”

Yeahmobi stated that it will continue expanding its collaboration with Amazon Ads to support brands navigating increasingly complex global media environments.

About Yeahmobi
Yeahmobi is a global marketing brand focused on helping businesses achieve international growth through digital advertising, data-driven operations, and AI-powered marketing solutions.

Forward-Looking Statements
This press release contains forward-looking statements. Actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update any forward-looking statements.

 

View original content:https://www.prnewswire.com/news-releases/eclicktech-attends-amazon-ads-unboxed-2026-highlighting-four-key-trends-shaping-ai-driven-global-marketing-302767470.html

SOURCE Yeahmobi

Continue Reading

Trending